Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling
Annika Gesiorowski(Heinrich Heine University Düsseldorf), Jürgen Scheller(Heinrich Heine University Düsseldorf)
Cited by 17
Related Papers
Targeting IL-6 trans-signalling: past, present and future prospects
|Nature reviews. Immunology|2023|453
Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor
|Journal of Biological Chemistry|2011|206
Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling
|Biochemical Journal|2006|53
Alternative Intronic Polyadenylation Generates the Interleukin-6 Trans-signaling Inhibitor sgp130-E10
|Journal of Biological Chemistry|2014|44